Tibet Rhodiola Pharmaceutical Holding Co. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 704.22 million compared to CNY 906.94 million a year ago.

Revenue was CNY 704.22 million compared to CNY 906.94 million a year ago. Net income was CNY 312.92 million compared to CNY 303.2 million a year ago. Basic earnings per share from continuing operations was CNY 0.9692 compared to CNY 0.9385 a year ago.

Diluted earnings per share from continuing operations was CNY 0.9692 compared to CNY 0.9385 a year ago.